How PlexusDx Supports a More Personalized Approach PlexusDx's approach to compounded tirzepatide combines medication access with genetic personalization
Systemic inflammatory markers in neuropathic pain, nerve injury, and recovery
Contact your healthcare provider immediately if you experience: Severe or persistent abdominal pain , particularly if localized to the upper abdomen or accompanied by back pain, which could indicate pancreatitisa rare but serious adverse effect documented in tirzepatide clinical trials Right upper quadrant pain, fever, or yellowing of skin/eyes , which may indicate acute gallbladder disease, a known risk with tirzepatide therapy Persistent nausea and vomiting that prevents adequate oral intake or leads to signs of dehydration (decreased urination, dizziness, dry mouth, extreme thirst) Severe diarrhea lasting more than 48 hours or accompanied by fever, bloody stools, or severe cramping, which may indicate gastrointestinal infection or other complications Severe abdominal distention, inability to pass gas or stool, and persistent vomiting , which could indicate intestinal obstruction Inability to tolerate any food or liquids for more than 24 hours, as this poses risks for dehydration and electrolyte imbalances Unexplained weight loss beyond expected therapeutic effects, or difficulty maintaining adequate nutrition Patients taking tirzepatide with insulin or sulfonylureas should also be alert for hypoglycemia symptoms (shakiness, dizziness, sweating, confusion) and seek prompt care if severe
In-clinic visits are available at our Lacey, WA office
Our group has lately demonstrated that AITC causes a shift in the cell cycle distribution, leads to a disintegration of microtubules and inhibition of the actin-dependent intracellular transport in A
